Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Treatment with Eptinezumab Reduces Brain Fog and Increases the Number of Good Days Per Month in Patients with Chronic Migraine in a Real-world Setting
Headache
P8 - Poster Session 8 (5:30 PM-6:30 PM)
12-009

Migraine-associated “brain fog” can occur as an ictal or interictal manifestation and negatively impact many aspects of life.

To evaluate the real-world effectiveness of eptinezumab on “brain fog” and the number of “good” days/month in adults with chronic migraine (CM).

REVIEW, an observational, multi-site (4 tertiary headache centers), US-based study, was conducted to evaluate real-world experiences of patients with CM treated with eptinezumab for migraine prevention. Included patients (≥18 years) were diagnosed with CM and had completed ≥2 consecutive eptinezumab infusion cycles. Reported data are from a cross-sectional, post-eptinezumab patient survey. Patients ranked symptom bothersomeness and self-reported number of “good” days/month before and after eptinezumab. Patients reported if they ever experienced “brain fog,” defined as feeling confused, having difficulty learning or remembering, or having trouble speaking or reading before eptinezumab, and rated improvement after eptinezumab.
Ninety-four patients enrolled (female: 83%; mean age: 49 years; mean migraine diagnosis duration: 15 years). Before starting preventive treatment, “difficulty concentrating or thinking clearly” (78%) was ranked as the third most bothersome symptom following “head pain” and “head pain worsening with movement.” Eighty percent of patients reported ever experiencing “brain fog”. After eptinezumab, 86% reported some level of improvement and 63% reported moderate to complete improvement. Those who reported complete/very much improvement in “brain fog” had a 15-day increase in number of “good” days compared with a 1-day improvement in those whose “brain fog” did not improve. 
In this clinical-based study, “brain fog” was commonly reported (80%) and identified as a very/extremely bothersome symptom in patients with CM. Eighty-six percent reported some level of “brain fog” improvement after eptinezumab which was associated with more “good” days/month. Improvement in cognitive burden is an important target in CM and further research is needed to fully understand the impact of preventive therapies.
Authors/Disclosures
Neha Kapur
PRESENTER
Neha Kapur has received personal compensation for serving as an employee of Lundbeck. An immediate family member of Neha Kapur has stock in Doordash.
Dawn C. Buse, PhD (Dawn C. Buse, PhD) Dr. Buse has received personal compensation for serving as an employee of Vector Psychometric Group. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abbvie-Allergan. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amgen. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lilly. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lundbeck. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Collegium. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Teva. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lilly. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Abbvie-Allergan. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lundbeck. Dr. Buse has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Current Pain and Headache Reports. The institution of Dr. Buse has received research support from Amgen. The institution of Dr. Buse has received research support from FDA. The institution of Dr. Buse has received research support from National Headache Foundation.
Seema Soni-Brahmbhatt Seema Soni-Brahmbhatt has nothing to disclose.
Divya Asher Divya Asher has received personal compensation for serving as an employee of Lundbeck. Divya Asher has received personal compensation for serving as an employee of AbbVie.
Richard B. Lipton, MD, FAAN (Albert Einstein College of Medicine) Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Allergan/Abbvie. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Amgen. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Biohaven. Dr. Lipton has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Eli Lilly. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Lundbeck. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for GlaxoSmithKline. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Teva. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Vedanta. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Grifols. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Pfizer. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Axon. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Satsuma. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cool Tech. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BDSI. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Linpharma. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Allergan/Abbvie. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biohaven. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eli Lilly. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lundbeck. Dr. Lipton has stock in Biohaven. Dr. Lipton has stock in Manistee. Dr. Lipton has stock in Axon. Dr. Lipton has stock in CoolTech. The institution of Dr. Lipton has received research support from Teva. The institution of Dr. Lipton has received research support from Amgen. The institution of Dr. Lipton has received research support from Allergan/Abbvie. The institution of Dr. Lipton has received research support from Gammacore. The institution of Dr. Lipton has received research support from Axsome. The institution of Dr. Lipton has received research support from Charleston Labs. The institution of Dr. Lipton has received research support from Eli Lilly. The institution of Dr. Lipton has received research support from Satsuma. The institution of Dr. Lipton has received research support from NIH . The institution of Dr. Lipton has received research support from Veterans Administration. Dr. Lipton has received publishing royalties from a publication relating to health care.